Bolton-based Muto Longevity secures £50k for cellular health nutraceuticals

Targeting the preventative health market, Muto Longevity Limited has raised an estimated £50k to support the production of its clinical-grade longevity nutraceuticals. Based in Bolton, the company manufactures supplements designed to support cellular health and energy production by targeting six biological pathways, including NAD+ levels. These products are aimed at millennials and high-performance individuals seeking evidence-led recovery and preventative health solutions.

The company was incorporated in 2024. Its most recent financial accounts for the year ended 31 March 2025 show that the business operated with a headcount of one employee. Detailed financial metrics, including total assets, revenue, and profit or loss figures, were not disclosed in the public filing for that period.

This funding round follows the appointment of Alexander James Ayin as a director in March 2026. Formal documentation for the £50k allotment was filed in May 2026. The company focuses on providing clinical-grade solutions for individuals looking to manage biological aging through nutritional intervention. The nutraceuticals are formulated to address specific biological pathways that contribute to overall cellular energy and health maintenance.